ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VENN Venn Life Sciences Holdings Plc

6.85
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life Sciences Holdings Plc LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.85 6.70 7.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Open Orphan PLC Exercise of Warrants (5656B)

11/06/2021 7:00am

UK Regulatory


Venn Life Sciences (LSE:VENN)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Venn Life Sciences Charts.

TIDMORPH

RNS Number : 5656B

Open Orphan PLC

11 June 2021

11 June 2021

Open Orphan plc

("Open Orphan", the "Company")

Exercise of Warrants

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors, who participated in the Venn loan note financing in December 2018, over 404,806 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 0.1 pence per share for 143,312 Ordinary Shares and at a price of 2.2 pence per share for 261,494 Ordinary Shares. The gross proceeds of this exercise received by the Company amount to GBP5,896.18.

Following this exercise, the warrants issued to investors in connection with the 2018 Venn loan note have been substantially exercised with only the Chairman's 657,285 warrants outstanding.

The total outstanding warrants over Ordinary Shares are as follows:

 
 Number of    Exercise      Date awarded    Expiry Date           Beneficiary 
  Ordinary    Price per 
   Shares       share 
----------  -----------  -----------------  ------------    ----------------------- 
  232,696    0.1 pence    11 December 2018  10 December     Venn loan note investor 
                                                2023 
  424,589    2.2 pence    11 December 2018  10 December     Venn loan note investor 
                                                2023 
 1,607,142   5.6 pence      28 June 2019    27 June 2024          An advisor 
 

The Company has made application for 404,806 new Ordinary Shares, to be issued and allotted as a result of the warrant exercise set out above, to be admitted to trading on AIM and Euronext Growth. Admission is expected to occur at 8.00 a.m. on 16 June 2021.

Total Voting Rights

Following the admission of the 404,806 new Ordinary Shares, the Company's total issued ordinary share capital will consist of 670,855,002 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com . By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com .

For further information, please contact:

 
 Open Orphan plc                                                          www.openorphan.com 
 Cathal Friel, Executive Chairman                                        +353 (0) 1 644 0007 
 
 Arden Partners plc (Nominated Adviser 
  and Joint Broker)                                                     +44 (0) 20 7614 5900 
 John Llewellyn-Lloyd / Richard Johnson 
  / Oscair McGrath 
 
 finnCap plc (Joint Broker)                                             +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson/ Richard 
  Chambers 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                                +353 (0) 1 679 6363 
 Anthony Farrell 
 
 Walbrook PR (Financial PR & IR)            +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
 Paul McManus / Sam Allen /                            +44 (0)7980 541 893 / +44 (0)7748 651 
  Lianne Cawthorne                                                                     727 / 
                                                                         +44 (0)7584 391 303 
 
 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFZGMVZGVGMZZ

(END) Dow Jones Newswires

June 11, 2021 02:00 ET (06:00 GMT)

1 Year Venn Life Sciences Chart

1 Year Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

Your Recent History

Delayed Upgrade Clock